1. ALLA AKTIER
  2. NYHETER
  3. CHORDATE MEDICAL

Chordate Medical

Nyheter Chordate Medical Nyheter alla bolag

Interview: Italian professor on new successful K.O.S study: "A very valuable tool"

In a new interview with Biostock, principal investigator Dr. Lino Di Rienzo Businco discusses the new study titled "Effectiveness of Kinetic Oscillation Stimulation Treatment in Persistent Moderate-Severe Allergic Rhinitis Compared to Medical Therapy". The study shows that Chordate's K.O.S treatment improves nasal airflow more effectively than medical therapy alone in cases of persistent moderate to severe allergic rhinitis. Dr. Businco is an otolaryngologist, an expert in sports medicine, and has been treating patients with K.O.S for several years, including top athletes in Italy's Olympic team.

"Key take away is the capability of K.O.S to complete the effectiveness of the standard medical care for allergic rhinitis with a very effective, non-invasive treatment and high patient compliance. Nasal obstruction, runny nose, nasal discharge, itching, and sneezing are better controlled when adding  an effective treatment against neurogenic inflammation. Otherwise, symptoms are not always well controlled in this special group of patients with moderate to severe allergic rhinitis," says Dr. Businco to Biostock.

Chordate Medical has not previously investigated the effects of K.O.S on allergic rhinitis to a significant extent, which means that the study results open up new potential opportunities for the company.

"The innovative concept is that K.O.S not only has a positive effect on non-allergic patients, but even on allergic patients in an effective way to better control the symptoms and improve the efficiency of standard drugs such as nasal sprays, steroid sprays, and antihistamines, and perhaps even reduce the need for these medications with their associated side effects", says Dr. Businco.

Watch the full interview with Dr. Lino Di Rienzo Businco

For more information, please contact:
Anders Weilandt, CEO
anders.weilandt@chordate.com
Cell: +46 733-874277

About Chordate
Chordate Medical Holding AB (publ) is a medical technology company that has developed, patented and CE-marked a neuromodulation and drug-free treatment technology for chronic migraine and chronic nasal congestion (rhinitis), Kinetic Oscillation Stimulation (K.O.S). The treatment has clinically proven efficacy according to a recent study, and is marketed in Finland, Germany, the UK, Italy, Israel, and Saudi Arabia. Chordate Medical is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH). Read more at www.chordate.com

The company's Certified Adviser on Nasdaq First North Growth Market Stockholm is Västra Hamnen Corporate Finance AB.

N.B. The English text is an in-house translation of the original Swedish text. Should there be any disparities between the Swedish and the English text, the Swedish text shall prevail.

Attachments
Interview: Italian professor on new successful K.O.S study: "A very valuable tool"

Datum 2023-06-12, kl 08:20
Källa MFN
Bifogade filer
Interview: Italian professor on new successful K.O.S study: "A very valuable tool"
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 10 000 unika besökare per månad. Vår discord har över 5000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!